Short-term Therapeutic Effect of Recombinant Human Endostatin Combined with Cis-platinum on Malignant Pleural Effusions: A Meta-analysis
10.3870/j.issn.1004-0781.2017.05.022
- VernacularTitle:重组人血管内皮抑素联合顺铂胸腔灌注治疗恶性胸腔积液近期疗效的Meta分析
- Author:
Chuanfeng LYU
;
Shan WANG
;
Fang YUAN
;
Jia YAO
;
Xiaoxue GONG
;
Donglou LIANG
;
Yujin GUO
- Keywords:
Recombinant human endostatin;
Cis-platinum;
Pleural effusions,malignant;
Meta-analysis
- From:
Herald of Medicine
2017;36(5):558-563
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of recombinant human endostatin (rh-endostatin) combined with cis-platinum for patients with malignant pleural effusions.Methods A computer-based online search was performed through Elsevier, PubMed, Medline, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese BioMedical Literature Database and Wanfang Database.According to the inclusion and exclusion criteria, the randomized controlled trials about short-term therapeutic effect of rh-endostatin combined with cis-platinum on malignant pleural effusions published until December 2015 were selected.Quality of the studies was assessed using modified Jadad scale.After data extraction, a Meta-analysis was performed by RevMan 5.3 software.Relative risk (RR) and its 95% confidence interval (CI) were calculated.The Egger test was performed by Stata 12.0 software.Results Fourteen eligible randomized controlled trials were included in this Meta-analysis involving 1 330 patients,665 in cis-platinum alone group(control group), and 665 in rh-endostatin combined with cis-platinum group(treatment group).The results showed that there were significant improvements in overall response rate (ORR) [73.53% vs 45.41%,RR=1.62,95%CI(1.47,1.78),P<0.000 01] and the rate of quality of life improvement [71.65% vs 46.94%,RR=1.52,95%CI(1.38,1.68),P<0.000 01] in the treatment group, as compared with those of the control group.Meanwhile, there were no statistically significant differences in the rate of cardio toxicity [10.38% vs 5.77%,RR=1.73,95%CI(0.99,3.03),P=0.06].Conclusion This Meta-analysis indicated that in comparison with cis-platinum alone, rh-endostatin combined with cis-platinum has a better therapeutic effect on malignant pleural effusions.
